-
公开(公告)号：US09114131B2
公开(公告)日：2015-08-25
申请号：US13877779
申请日：2011-10-04
申请人： Ichiro Watanabe , Yoshiharu Hiruma , Eisuke Tsuda , Tatsuji Matsuoka , Toshiaki Ohtsuka , Tohru Takahashi , Toshinori Agatsuma , Sandra Miller , Robert Mühlbacher , Kathrin-Ladetzki Baehs , Steffen Runz , Ulrike Schubert , Ingrid Schuster , Dirk Ponsel
发明人： Ichiro Watanabe , Yoshiharu Hiruma , Eisuke Tsuda , Tatsuji Matsuoka , Toshiaki Ohtsuka , Tohru Takahashi , Toshinori Agatsuma , Sandra Miller , Robert Mühlbacher , Kathrin-Ladetzki Baehs , Steffen Runz , Ulrike Schubert , Ingrid Schuster , Dirk Ponsel
IPC分类号： A61K39/00 , A61K39/395 , C07K16/00 , C07K16/22 , C12N5/10 , C12N15/11 , C12N15/63 , C07K16/28 , A61K45/06
CPC分类号： A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/2803 , C07K2317/21 , C07K2317/55 , C07K2317/92
摘要： An isolated antibody capable of binding Siglec-15 which inhibits osteoclast formation and/or osteoclastic bone resorption, or a functional fragment thereof. The heavy chain of the antibody comprises a CDRH1 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 106, a CDRH2 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 107, and a CDRH3 comprising a sequence having at least 80% sequence identity to one of SEQ ID NOS: 35, 45, 55, 65 or 80. The light chain of the antibody comprises a CDRL1 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 73 or 83, a CDRL2 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 108, and a CDRL3 comprising a sequence having at least 80% sequence identity to one of SEQ ID NOS: 40, 50, 60, 70, 90, 100 or 109.
摘要翻译： 能够结合抑制破骨细胞形成和/或破骨细胞骨吸收的Siglec-15的分离抗体或其功能片段。 抗体的重链包含CDRH1，其包含与SEQ ID NO：106具有至少80％序列同一性的序列，CDRH2包含与SEQ ID NO：107具有至少80％序列同一性的序列，以及CDRH3，其包含 具有与SEQ ID NO：35,45,55,65或80之一具有至少80％序列同一性的序列。抗体的轻链包含CDRL1，其包含与SEQ ID NO：73具有至少80％序列同一性的序列 或83，CDRL2，其包含与SEQ ID NO：108具有至少80％序列同一性的序列，和CDRL3，其包含与SEQ ID NO：40,50,60,70， 90，100或109。
-
公开(公告)号：US20130280276A1
公开(公告)日：2013-10-24
申请号：US13877779
申请日：2011-10-04
申请人： Ichiro Watanabe , Yoshiharu Hiruma , Eisuke Tsuda , Tatsuji Matsuoka , Toshiaki Ohtsuka , Tohru Takahashi , Toshinori Agatsuma , Sandra Miller , Robert Mühlbacher , Kathrin-Ladetzki Baehs , Steffen Runz , Ulrike Schubert , Ingrid Schuster , Dirk Ponsel
发明人： Ichiro Watanabe , Yoshiharu Hiruma , Eisuke Tsuda , Tatsuji Matsuoka , Toshiaki Ohtsuka , Tohru Takahashi , Toshinori Agatsuma , Sandra Miller , Robert Mühlbacher , Kathrin-Ladetzki Baehs , Steffen Runz , Ulrike Schubert , Ingrid Schuster , Dirk Ponsel
IPC分类号： A61K39/395 , A61K45/06
CPC分类号： A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/2803 , C07K2317/21 , C07K2317/55 , C07K2317/92
摘要： An isolated antibody capable of binding Siglec-15 which inhibits osteoclast formation and/or osteoclastic bone resorption, or a functional fragment thereof. The heavy chain of the antibody comprises a CDRH1 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 106, a CDRH2 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 107, and a CDRH3 comprising a sequence having at least 80% sequence identity to one of SEQ ID NOS: 35, 45, 55, 65 or 80. The light chain of the antibody comprises a CDRL1 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 73 or 83, a CDRL2 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 108, and a CDRL3 comprising a sequence having at least 80% sequence identity to one of SEQ ID NOS: 40, 50, 60, 70, 90, 100 or 109.
摘要翻译： 能够结合抑制破骨细胞形成和/或破骨细胞骨吸收的Siglec-15的分离抗体或其功能片段。 抗体的重链包含CDRH1，其包含与SEQ ID NO：106具有至少80％序列同一性的序列，CDRH2包含与SEQ ID NO：107具有至少80％序列同一性的序列，以及CDRH3，其包含 具有与SEQ ID NO：35,45,55,65或80之一具有至少80％序列同一性的序列。抗体的轻链包含CDRL1，其包含与SEQ ID NO：73具有至少80％序列同一性的序列 或83，CDRL2，其包含与SEQ ID NO：108具有至少80％序列同一性的序列，和CDRL3，其包含与SEQ ID NO：40,50,60,70， 90，100或109。
-
公开(公告)号：US09403909B2
公开(公告)日：2016-08-02
申请号：US13206736
申请日：2011-08-10
申请人： Reimi Kawaida , Toshiaki Ohtsuka , Toshinori Agatsuma , Philip Rodley , Sandra Miller , Ulrike Schubert
发明人： Reimi Kawaida , Toshiaki Ohtsuka , Toshinori Agatsuma , Philip Rodley , Sandra Miller , Ulrike Schubert
IPC分类号： A61K39/395 , C07K16/28 , A61K39/00
CPC分类号： C07K16/2863 , A61K39/39558 , A61K2039/505 , C07K2317/21 , C07K2317/24 , C07K2317/33 , C07K2317/55 , C07K2317/565 , G01N2333/9121
摘要： The present disclosure provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for MST1R, which plays an integral role in various disorders or conditions, such as cancer. These antibodies, accordingly, can be used to treat these and other disorders and conditions. Antibodies of the disclosure also can be used in the diagnostics field, as well as for further investigating the role of MST1R in the progression of disorders associated with tumors. The disclosure also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.
摘要翻译： 本公开提供了重组抗原结合区和包含对MST1R特异性的这种抗原结合区的功能片段，其在各种疾病或病症例如癌症中起积体作用。 因此，这些抗体可用于治疗这些和其他病症和病症。 本公开的抗体也可用于诊断领域，以及用于进一步研究MST1R在与肿瘤相关的疾病进展中的作用。 本公开还提供了编码前述抗体的核酸序列，含有该抗体的载体，药物组合物和具有使用说明书的试剂盒。
-
公开(公告)号：US20120034215A1
公开(公告)日：2012-02-09
申请号：US13206736
申请日：2011-08-10
申请人： Reimi Kawaida , Toshiaki Ohtsuka , Toshinori Agatsuma , Philip Rodley , Sandra Miller , Ulrike Schubert
发明人： Reimi Kawaida , Toshiaki Ohtsuka , Toshinori Agatsuma , Philip Rodley , Sandra Miller , Ulrike Schubert
IPC分类号： A61K39/395 , C12N15/13 , A61P35/00 , C12P21/00 , C12N5/10 , C12N1/21 , C12N5/071 , C07K16/28 , C12N15/63
CPC分类号： C07K16/2863 , A61K39/39558 , A61K2039/505 , C07K2317/21 , C07K2317/24 , C07K2317/33 , C07K2317/55 , C07K2317/565 , G01N2333/9121
摘要： The present disclosure provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for MST1R, which plays an integral role in various disorders or conditions, such as cancer. These antibodies, accordingly, can be used to treat these and other disorders and conditions. Antibodies of the disclosure also can be used in the diagnostics field, as well as for further investigating the role of MST1R in the progression of disorders associated with tumors. The disclosure also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.
摘要翻译： 本公开提供了重组抗原结合区和包含对MST1R特异性的这种抗原结合区的功能片段，其在各种疾病或病症例如癌症中起积体作用。 因此，这些抗体可用于治疗这些和其他病症和病症。 本公开的抗体也可用于诊断领域，以及用于进一步研究MST1R在与肿瘤相关的疾病进展中的作用。 本公开还提供了编码前述抗体的核酸序列，含有该抗体的载体，药物组合物和具有使用说明书的试剂盒。
-
公开(公告)号：US08449882B2
公开(公告)日：2013-05-28
申请号：US12713041
申请日：2010-02-25
申请人： Jun Hasegawa , Toshiaki Ohtsuka , Atsushi Urano , Junko Yamaguchi , Toshinori Agatsuma , Kaori Nakahara , Takeshi Takizawa
发明人： Jun Hasegawa , Toshiaki Ohtsuka , Atsushi Urano , Junko Yamaguchi , Toshinori Agatsuma , Kaori Nakahara , Takeshi Takizawa
IPC分类号： A61K39/395
CPC分类号： C07K16/28 , A61K2039/505 , C07K16/2866 , C07K16/30 , C07K2317/24 , C07K2317/51 , C07K2317/515 , C07K2317/56 , C07K2317/732 , C07K2317/734 , C07K2317/76
摘要： Problem to Be SolvedIt is intended to provide an antibody having an inhibitory activity against cell malignant transformation and/or tumor cell growth, etc.SolutionThe present invention provides an antibody which recognizes an epitope recognized by an antibody produced by a hybridoma SH348-1 (FERM BP-10836) or a hybridoma SH357-1 (FERM BP-10837), an antibody produced by the hybridoma SH348-1 or the hybridoma SH357-1, an antibody obtained by humanizing the antibody produced by the hybridoma SH348-1 or the hybridoma SH357-1, a pharmaceutical agent comprising the antibody as an active ingredient, etc.
摘要翻译： 要解决的问题旨在提供具有抑制细胞恶性转化和/或肿瘤细胞生长等的活性的抗体。溶液本发明提供一种抗体，其识别由杂交瘤SH348-1产生的抗体识别的表位 （FERM BP-10836）或杂交瘤SH357-1（FERM BP-10837），由杂交瘤SH348-1或杂交瘤SH357-1产生的抗体，通过将由杂交瘤SH348-1产生的抗体人源化而获得的抗体或 杂交瘤SH357-1是包含抗体作为活性成分的药剂等
-
公开(公告)号：US20100183618A1
公开(公告)日：2010-07-22
申请号：US12713041
申请日：2010-02-25
申请人： Jun Hasegawa , Toshiaki Ohtsuka , Atsushi Urano , Junko Yamaguchi , Toshinori Agatsuma , Kaori Nakahara , Takeshi Takizawa
发明人： Jun Hasegawa , Toshiaki Ohtsuka , Atsushi Urano , Junko Yamaguchi , Toshinori Agatsuma , Kaori Nakahara , Takeshi Takizawa
CPC分类号： C07K16/28 , A61K2039/505 , C07K16/2866 , C07K16/30 , C07K2317/24 , C07K2317/51 , C07K2317/515 , C07K2317/56 , C07K2317/732 , C07K2317/734 , C07K2317/76
摘要： Problem to Be SolvedIt is intended to provide an antibody having an inhibitory activity against cell malignant transformation and/or tumor cell growth, etc.SolutionThe present invention provides an antibody which recognizes an epitope recognized by an antibody produced by a hybridoma SH348-1 (FERM BP-10836) or a hybridoma SH357-1 (FERM BP-10837), an antibody produced by the hybridoma SH348-1 or the hybridoma SH357-1, an antibody obtained by humanizing the antibody produced by the hybridoma SH348-1 or the hybridoma SH357-1, a pharmaceutical agent comprising the antibody as an active ingredient, etc.
摘要翻译： 要解决的问题旨在提供具有抑制细胞恶性转化和/或肿瘤细胞生长等的活性的抗体。溶液本发明提供一种抗体，其识别由杂交瘤SH348-1产生的抗体识别的表位 （FERM BP-10836）或杂交瘤SH357-1（FERM BP-10837），由杂交瘤SH348-1或杂交瘤SH357-1产生的抗体，通过将由杂交瘤SH348-1产生的抗体人源化而获得的抗体或 杂交瘤SH357-1是包含抗体作为活性成分的药剂等
-
公开(公告)号：US07855056B2
公开(公告)日：2010-12-21
申请号：US10548688
申请日：2004-03-09
IPC分类号： G01N33/53
CPC分类号： C07K16/30 , C07K2317/732 , C12Q1/6886 , C12Q2600/136 , C12Q2600/158
摘要： The present invention relates to a method of detecting cancer by use of an oncogene, a method of screening for an active compound useful to treat and/or prevent cancer, and a pharmaceutical composition for treatment and/or prevention of cancer. More specifically, the present invention provides a method of detecting cancer based on the expression of the human oculospanin gene as a marker and a pharmaceutical composition containing an antibody capable of specifically recognizing human oculospanin and having cytotoxic activity against cancer cells.
摘要翻译： 本发明涉及通过使用癌基因检测癌症的方法，筛选用于治疗和/或预防癌症的活性化合物的方法和用于治疗和/或预防癌症的药物组合物。 更具体地，本发明提供了一种基于人oculospanin基因作为标记物的表达和含有能够特异性识别人oculospanin并对癌细胞具有细胞毒性活性的抗体的药物组合物来检测癌症的方法。
-
公开(公告)号：US20070166312A1
公开(公告)日：2007-07-19
申请号：US10548688
申请日：2004-03-09
IPC分类号： A61K39/395 , C07K16/30 , C12Q1/68 , G01N33/574
CPC分类号： C07K16/30 , C07K2317/732 , C12Q1/6886 , C12Q2600/136 , C12Q2600/158
摘要： The present invention relates to a method of detecting cancer by use of an oncogene, a method of screening for an active compound useful to treat and/or prevent cancer, and a pharmaceutical composition for treatment and/or prevention of cancer. More specifically, the present invention provides a method of detecting cancer based on the expression of the human oculospanin gene as a marker and a pharmaceutical composition containing an antibody capable of specifically recognizing human oculospanin and having cytotoxic activity against cancer cells.
摘要翻译： 本发明涉及通过使用癌基因检测癌症的方法，筛选用于治疗和/或预防癌症的活性化合物的方法和用于治疗和/或预防癌症的药物组合物。 更具体地，本发明提供了一种基于人oculospanin基因作为标记物的表达和含有能够特异性识别人oculospanin并对癌细胞具有细胞毒性活性的抗体的药物组合物来检测癌症的方法。
-
公开(公告)号：US20060127405A1
公开(公告)日：2006-06-15
申请号：US11223812
申请日：2005-09-09
IPC分类号： A61K39/395 , C12Q1/68 , G01N33/574 , C07H21/04 , C12P21/06 , C12N5/06
CPC分类号： C07K16/30 , C07K2317/732 , C12Q1/6886 , C12Q2600/136 , C12Q2600/158
摘要： The present invention relates to a method of detecting cancer by use of an oncogene, a method of screening for an active compound useful to treat and/or prevent cancer, and a pharmaceutical composition for treatment and/or prevention of cancer. More specifically, the present invention provides a method of detecting cancer based on the expression of the human oculospanin gene as a marker and a pharmaceutical composition containing an antibody capable of specifically recognizing human oculospanin and having cytotoxic activity against cancer cells.
摘要翻译： 本发明涉及通过使用癌基因检测癌症的方法，筛选用于治疗和/或预防癌症的活性化合物的方法和用于治疗和/或预防癌症的药物组合物。 更具体地，本发明提供了一种基于人oculospanin基因作为标记物的表达和含有能够特异性识别人oculospanin并对癌细胞具有细胞毒性活性的抗体的药物组合物来检测癌症的方法。
-
公开(公告)号：US07741447B2
公开(公告)日：2010-06-22
申请号：US11872479
申请日：2007-10-15
IPC分类号： C07K16/30 , A61K39/395
CPC分类号： C07K16/30 , C07K2317/732 , C12Q1/6886 , C12Q2600/136 , C12Q2600/158
摘要： The present invention relates to a method of detecting cancer by use of an oncogene, a method of screening for an active compound useful to treat and/or prevent cancer, and a pharmaceutical composition for treatment and/or prevention of cancer. More specifically, the present invention provides a method of detecting cancer based on the expression of the human oculospanin gene as a marker and a pharmaceutical composition containing an antibody capable of specifically recognizing human oculospanin and having cytotoxic activity against cancer cells.
-
-
-
-
-
-
-
-
-
搜索结果
14 条记录 (耗时 0.059 秒)
